<SEC-DOCUMENT>0001571049-17-007255.txt : 20170807
<SEC-HEADER>0001571049-17-007255.hdr.sgml : 20170807
<ACCEPTANCE-DATETIME>20170807092526
ACCESSION NUMBER:		0001571049-17-007255
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170807
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170807
DATE AS OF CHANGE:		20170807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		171010269

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1702303_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 7, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(State or other jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(IRS Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>of incorporation)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>200 Connell
Drive, Suite 1500</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922</B></FONT><BR>
<FONT STYLE="font-size: 8pt"><B>(Address of principal executive offices and zip code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). <FONT STYLE="font-family: Wingdings">&uml;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">On August 7, 2017,
Cyclacel Pharmaceuticals, Inc. issued a press release announcing the selection of a recommended Phase 2 dose from part 1 of a dose-escalating,
Phase 1, first-in-human clinical study of CYC065, a Cyclin Dependent Kinase 2/9 inhibitor. A copy of the press release is attached
as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Item&nbsp;9.01 Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(d)&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 84%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press release, dated August 7, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 7, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 15%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 84%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press release, dated August 7, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1702303_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 63%; font-size: 10pt"><IMG SRC="t1702303_ex99-1img1.jpg" ALT=""></td>
    <td style="width: 37%; font-size: 10pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="t1702303_ex99-1img2.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL ANNOUNCES SELECTION OF RECOMMENDED
PHASE 2 DOSE FOR CYC065</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND EVIDENCE OF DURABLE TARGET ENGAGEMENT
AND MCL-1 BIOMARKER SUPPRESSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>- Part 2 of study will focus on cyclin
E amplified drug resistant solid tumors -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Berkeley Heights, NJ, August 7, 2017 </B>&ndash; Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a clinical-stage biopharmaceutical company using
cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and
other proliferative diseases, announced today the selection of a recommended Phase 2 dose (RP2D) from part 1 of a dose-escalating,
Phase 1, first-in-human, clinical study of CYC065, a Cyclin Dependent Kinase (CDK) 2/9 inhibitor. RP2D was determined to be dosing
level 6 which enrolled 9 evaluable patients with advanced cancers. Prolonged reduction of the Mcl-1 biomarker was observed in 7
out of the 9 patients for at least 24 hours following a single dose of CYC065, which was generally well tolerated. Preliminary
anticancer activity was observed in three patients with Mcl-1, MYC and Mcl-1/cyclin E amplified cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&ldquo;Our
early clinical results and selection of RP2D support progressing clinical evaluation of CYC065 in selected,
molecularly-defined, patient populations,&rdquo; said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
&ldquo;Durable reduction of Mcl-1 expression in the majority of patients at RP2D is an important differentiator, as other CDK
inhibitors only do so transiently. Like other CDK inhibitors, we expect CYC065 to work best in combination with existing
anticancer drugs. Indications of anticancer activity after a single dose of CYC065 alone in patients with molecular features
related to the drug&rsquo;s mechanism are unexpected and potentially exciting. We plan to apply part of the net proceeds from
our July financing to progress CYC065 studies, alone and in combinations, in both liquid and solid cancers with such
molecular features. There are currently no drugs available for patients with such features. Our highest priority is to
finalize designs for a Phase 1/2 study testing CYC065 in combination with venetoclax, a Bcl-2 inhibitor approved for chronic
lymphocytic leukemia, where we believe Mcl-1 suppression will be beneficial, while in parallel enrolling a new part 2 of the
Phase 1 study in patients with advanced solid tumors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Phase 1 first-in-human trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The objective of part 1 of the <FONT STYLE="color: #373945">Phase
1 dose escalating, monotherapy </FONT>study was to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and identify RP2D.
Certain key features of the trial are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; color: #373945">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #373945"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">24 heavily treated patients with various advanced solid tumors were
enrolled;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #373945">The trial advanced through seven DL cohorts with a
range of 8 to 288 mg/m<SUP>2</SUP>/day, administered as a </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">4-hour
intravenous infusion once every 3 weeks;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dose limiting toxicity at DL7 was reversible neutropenia, febrile
neutropenia and diarrhea;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #373945"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ten patients were treated at DL6, of which 9 are evaluable at present;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; color: #373945">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #373945">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #373945"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PK parameters have demonstrated dose proportional increases in CYC065
exposure with increasing dosing levels;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A biologically effective dose was established from analysis of surrogate
tissue, supporting a RP2D of 192 mg/m<SUP>2</SUP>/day;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #373945">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consistent<FONT STYLE="color: #373945"> Mcl-1 suppression over 24
hours after a single dose was observed in 7 out of 9 evaluable patients at DL6; and</FONT></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #373945"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anticancer activity was reported by the investigators in patients
with Mcl-1 (ovarian cancer: reduction of CA-125 tumor marker levels), MYC<I> </I>(larynx: radiographic tumor shrinkage)<I> </I>and
Mcl-1/cyclin E (ovarian: radiographic tumor shrinkage) amplified tumors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; color: #373945">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Having successfully achieved the objectives of part 1 of the
study, part 2 has been initiated aiming to enroll patients with advanced solid tumors, and in particular cyclin E amplified tumors.
Such tumors include subsets of high grade serous ovarian and uterine cancers. Part 2 will evaluate CYC065 in a more intensive schedule
for 2 days per week for 2 weeks of a three week cycle. Biospecimens will be collected for assessment of biomarkers related to CYC065&rsquo;s
mechanism of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CYC065</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel's second generation CDK2/9 inhibitor, CYC065, is being
evaluated in an ongoing, first-in-human, Phase 1 trial in patients with advanced solid tumors. In part 1, CYC065 was well tolerated,
there were robust and durable effects on the Mcl-1 biomarker and the recommended Phase 2 dose has been selected. Evidence of target
engagement was observed by decreases in target cyclin-dependent kinase substrate phosphorylation accompanied by robust and prolonged
Mcl-1 suppression in peripheral blood cells in patient samples from the study, consistent with the Company's preclinical data.
CYC065 is mechanistically similar but has much higher dose potency, <I>in vitro</I> and <I>in vivo,</I> and improved metabolic
stability than seliciclib, Cyclacel's first generation CDK inhibitor. As with palbociclib, the first CDK inhibitor approved by
FDA in 2015, and ribociclib approved in 2017, CYC065 may be most useful in combination with other anticancer agents, including
Bcl-2 antagonists, such as venetoclax, or HER2 inhibitors, such as trastuzumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">CYC065 is a highly-selective, orally-
and intravenously-available, second generation inhibitor of CDK2 and CDK9. It causes apoptotic death of cancer cells at sub-micromolar
concentrations. Antitumor efficacy has been achieved <I>in vivo</I> with once a day oral dosing at well tolerated doses in preclinical
models. Evidence from published nonclinical studies show that CYC065 may benefit patients with adult and pediatric hematological
malignancies, including certain Acute Myeloid Leukemias (AML), Acute Lymphocytic Leukemias (ALL), Chronic Lymphocytic Leukemias
(CLL), B-cell lymphomas, multiple myelomas, and certain solid tumors, including breast and uterine cancers and neuroblastomas.
Independent investigators published nonclinical evidence that CYC065 induced regression or tumor growth inhibition in a model of
HER2-positive breast cancer addicted to cyclin E that is resistant to trastuzumab, reduced tumor growth in models of CCNE1-amplified
uterine serous carcinoma and reduced tumor burden and prolonged survival in several neuroblastoma models <I>in vivo</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK
inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine
and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and exploratory
subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit
<U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
&quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
&quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company:</font></td>
    <TD STYLE="width: 80%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron, (908) 517-7330, <u>pmcbarron@cyclacel.com</u></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Relations:</font></td>
    <TD STYLE="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russo partners LLC, Alexander Fudukidis, (646) 942-5632,<BR>
 <u>alex.fudukidis@russopartnersllc.com</u></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in; color: #0563C1">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2017 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel<SUP>&reg;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1702303_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702303_ex99-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0P"U P$1  (1 0,1 ?_$ *<  0 " P$! 0$
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M9/N10$6S<R+0PH#6:N56F\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K\$0
M!$1   !$1$>@  ?$1$1^   <4K6Y<Q8K,S5D"Y J@L$62$FJ]"99_*$B7*[A
MJWF3.?)X?HJKIHHD#SN^6\A!+W]WPXI5.WJ^&/NF2]\]TID@+$LF1[!!5^7<
M%(D5&JPQGENED2%(<W@ 6)XDJGY>@ W+VC^(<Z[^X'UL5@>'=5Q393$%MQQ
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M;O9&C<#56)M[>!K-CPD^I=(A;I+0.6:XI(OUT+"V+-%9+MF*S@J#I%0!.8H
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M3@I75NW;MVC=!JU01;-6R*3=LV;I$1;MVZ)"IHH((IE*FDBDF4"E*4 *4H
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M*7;?&Q['I,FWMD.7*UI'B527E)'C<>-0$W"]6]:/(Y?SK)>OG&[^G,RLD/R
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C.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>t1702303_ex99-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702303_ex99-1img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P)- P$1  (1 0,1 ?_$ '   0 # 0 " P$
M       '" D&! 4! @,* 0$                     $   !0,# P,#! (#
M       ! @,$!0 &!]475Q$2ER$3""(4%3%!42,R0F%Q"1$!
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M_P II=#,3^>/841@-.1B&,<^N0@,+S=S3YK#OXY*!72*RE%U3>VFNOV-_=[
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MS4J>.6S!>MGV3)1#>&N:R(!G!JQL^V1?+/55C/7S15\Q=NRJE24,4QR&33*
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CKL_G(/;413]L;!*"JGO%7-WID_,?4FE['0X]?I$Y?Y] _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
